Sagimet Biosciences
PublicLast Round
Follow-on Offering
Jan 25, 2024
Total Funding Raised
$399.4M
Company Overview
Sagimet Biosciences (NAS: SGMT) is a biopharmaceutical company dedicated to developing selective fatty acid synthase (FASN) inhibitors for treating diseases linked to dysfunctional lipid metabolism, with its lead candidate, denifanstat, being an oral medication aimed at nonalcoholic steatohepatitis (NASH).
Sector
Healthcare
AI Layer
Non-AI
Keywords
selective fatty acid synthase (FASN) inhibitororal therapeutic for MASHMASH therapeutic developmentclinical-stage biopharmaceutical researchtherapeutic for liver fibrosis and inflammationmetabolic disease drug developmentsmall-molecule drug discoveryFASN inhibitor for acnebiopharmaceutical drug licensing modeloncology drug development via licensing
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Sagimet Biosciences Comps
Public and private peers based on sector, stage, and business model.
Sagimet Biosciences Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Follow-on Offering | Jan 25, 2024 | ||||
| IPO Announced | Jul 13, 2023 | ||||
| Growth Equity | Feb 11, 2021 | ||||
| Series E | Aug 5, 2019 | ||||
| Series D | Dec 30, 2014 | ||||
Series C | Jun 21, 2013 |
Sagimet Biosciences Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| The Column Group | Series B, Series C, Series A |
| New Enterprise Associates (NEA) | Series E, Growth Equity, Series B, Series C, Series D |
| Ally Bridge Group | Series D |
| Altium Capital | Growth Equity |
| The Chernin Group | Series B, Series A |
| TD Cowen | Follow-on Offering |
| HM Capital | Growth Equity |
Sagimet Biosciences Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Firmographic Details
HeadquartersSan Mateo, California
Employee Range26
Year Founded2007
Last FundingJan 25, 2024
